Targeting metabolic weaknesses in brain tumors with specific genetic changes
Official title: Targeting metabolic vulnerabilities induced by the 1p19q codeletion in oligodendrogliomas
Funded at University of California, San Francisco · NIH-10893486 · Data updated 2026-11-12
This study is looking at a type of brain tumor called oligodendroglioma to find new, gentler treatments that can stop the tumor from growing by targeting its energy sources, which could help patients feel better with fewer side effects.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | July 25, 2023 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $215,179 |
| NIH project number | 5R21CA277325-02 |
| Project ID | NIH-10893486 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with oligodendrogliomas that exhibit the 1p/19q codeletion.
✕Less likely to help
Patients with other types of brain tumors or those without the 1p/19q codeletion may not benefit from this research.
What this research studies
This research focuses on oligodendrogliomas, a type of brain tumor characterized by a specific genetic alteration known as the 1p/19q codeletion. The study aims to identify metabolic vulnerabilities in these tumors to develop targeted therapies that are less toxic than current treatments like chemotherapy and radiation. By inhibiting certain enzymes involved in tumor metabolism, the researchers hope to disrupt the growth of these tumors and improve patient outcomes. The approach involves using a combination of inhibitors to effectively target the tumor's energy production pathways.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less harmful treatment options for patients with oligodendrogliomas.
How similar studies have gone: Other research has shown promise in targeting metabolic pathways in cancer, suggesting that this approach could be effective for oligodendrogliomas as well.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Viswanath, Pavithra — University of California, San Francisco
- Study coordinator: Viswanath, Pavithra
Related research
Other NIH-funded projects on the same topics.
-
How cancer cells use exosomes to evade the immune system
This study is looking at how cancer cells use tiny bubbles called exosomes to hide proteins that can keep your immune system from fighting the tumor, and by figuring this out, the researchers hope to help doctors understand why some people respond well to cancer treatments while others don’t, ultimately aiming to creat
-
Reducing harm from smoking using electronic cigarettes
This study is looking at whether using electronic cigarettes can be a safer option for people who smoke traditional cigarettes, by comparing the health effects and exposure to harmful substances between the two.
-
Understanding how knee pain and knee obesity and muscle loss affect knee osteoarthritis
This project looks at how knee swelling, excess knee fat, and muscle loss relate to pain and structural changes in knee osteoarthritis in adults.
-
Cutaneous opioid signals in skin inflammation
A mentor-identified clinician-researcher at UCSF is studying how natural skin opioids regulate itch and pain in inflammatory skin conditions like eczema and hidradenitis, with plans to map where these opioids come from and how they affect skin nerves.
-
Pooling international data to understand long-term bisphosphonate use and atypical femur fractures
This project combines large patient datasets from multiple countries to understand how long-term bisphosphonate use relates to rare hip and thigh bone fractures, helping doctors and patients make safer treatment choices.
-
Airway cell and immune cell talks in lung transplant failure
This grant tests how airway cells and immune cells interact to drive chronic rejection after lung transplant, with the goal of slowing or preventing scar-like damage.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.